MedTrace Logo

Structured Case-Finding for Pancreatic Ductal Adenocarcinoma in Swiss Primary Care: A Feasibility Study

NCT07723781 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2026-07-23

No results posted yet for this study

Summary

Pancreatic ductal adenocarcinoma (PDAC) is diagnosed at an advanced, incurable stage in more than 80% of cases in Switzerland. Certain warning signs - new-onset diabetes, unexplained weight loss, or a family history of pancreatic cancer - may indicate elevated risk, but are not systematically assessed in primary care.

PANCATCH-Pilot tests whether a structured case-finding pathway in Swiss general practices is feasible. Adults aged 60 years or older with one or more of these risk factors are invited to undergo an MRI/MRCP examination of the pancreas and a blood draw for a blinded biomarker test (PancreaSure, Immunovia Inc.). Findings are reviewed by a multidisciplinary tumour board. The goal is not treatment, but to assess whether such a pathway works in the Swiss primary care context - as preparation for a larger national study.

The study enrolls 50 trigger-positive participants over 24 months through two parallel recruitment pathways: GP referral and self-presentation via a study website. Feasibility is assessed using six combined endpoints covering recruitment, process quality, safety, and equity.

Conditions

  • Pancreatic Adenocarcinoma (Ductal Adenocarcinoma)
  • Early Detection of Cancer

Interventions

DIAGNOSTIC_TEST

Structured case-finding pathway (MRI/MRCP + PancreaSure biomarker assay)

Single-visit structured pathway comprising: (1) standardised clinical risk assessment; (2) MRI/MRCP with macrocyclic gadolinium contrast agent (Dotarem) per PRECEDE consensus protocol; (3) blood draw for blinded PancreaSure serum biomarker assay (Immunovia Inc.) and study biobank; (4) multidisciplinary tumour board review. No therapeutic intervention.

Sponsors & Collaborators

  • OnkoZentrum Zürich AG

    collaborator OTHER

  • Krebsliga Schweiz

    collaborator UNKNOWN

  • Saskia Hendrich

    lead OTHER

Principal Investigators

  • Jan Schmidt, Professor · Swiss Surgery, Klinik Im Park, Hirslanden, Zurich

  • Alexander Siebenhüner, PD · Hirslanden Cancer Institute, Klinik Im Park, Zurich Role: Study Director

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-10-01
Primary Completion
2030-03-31
Completion
2030-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07723781 on ClinicalTrials.gov